The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020, which included updates to genetic testing choices and considerations as follows:- Choice of multi-gene panel may be guided by genes included, analyses offered, and financial assistance programs available for family testing
- Significant limitations in interpretations of polygenic risk scores:
- NOT recommended for use in clinical management; however, if being considered for use to guide clinical management, interpret and discuss in the context of Genetic Counseling/Results interpretation
- Recommend use in context of clinical trial
- VUS testing for family members should NOT be done for clinical purposes unless data exist to support discrepancy in results interpretation
You can check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf